The advent of novel immunotherapies such as blinatumomab (CD19-targeting bispecific T-cell engager) and inotuzumab ozogamicin (anti-CD22 antibody–drug conjugate) is associated with significantly prolonged event-free survival (EFS) and OS in both upfront and R/R disease continuing to change the treatment paradigm of patients with B-ALL [15,16,17]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.